Are there any obinutuzumab biosimilars available now?
Obinutuzumab (Gazyva) is an anti-CD20 cancer medicine. Whether a biosimilar is available depends on the country and on which biosimilar has actually received market authorization and launched.
From the information provided, no specific country, regulator (EMA/FDA/etc.), or named product was included, so I cannot confirm which obinutuzumab biosimilar brands are currently on the market.
Which countries are most likely to have an obinutuzumab biosimilar?
Biosimilars are typically first launched in regions with established approval pathways such as the EU (European Medicines Agency, EMA) and the UK (MHRA), then later in other markets depending on local regulatory decisions and company launches. Availability can differ even within Europe because of reimbursement rules and hospital procurement timing.
How can I check if a biosimilar is available where you live?
You can verify availability by checking:
- Your national medicines regulator’s biosimilar/interchangeable medicine pages (authorizations do not always equal “in stock”).
- The brand/biosimilar listing in your country’s official drug databases.
- Major oncology hospital formularies (biosimilars may require switching policies before they are used routinely).
What product name should I look for?
Biosimilar naming usually follows the originator plus a suffix (e.g., a different brand name from the originator). The key is to confirm it is specifically an obinutuzumab biosimilar (not another anti-CD20 antibody such as rituximab or ofatumumab).
If you tell me your country (and whether you mean retail pharmacy availability or hospital use), I can narrow this to the most relevant authorized biosimilar options and how to check them.
What if there is no obinutuzumab biosimilar yet in your market?
When an obinutuzumab biosimilar is not available, clinicians generally use:
- The originator product (Gazyva), or
- A different anti-CD20 option available as a biosimilar (for example, other antibodies with biosimilars already approved), depending on the exact cancer indication and treatment protocol.
Quick clarification
Which country/region are you asking about (e.g., US, UK, EU member state), and do you want availability for a specific cancer indication (like follicular lymphoma or CLL)?
Sources
No sources were provided with the question.